Adherium today announced it has released SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology, for AstraZeneca’s Turbuhaler medication. SmartTurbo Model 4 includes usability improvements to make the installation and removal of the Turbuhaler easier for older patients with COPD. The device also features a series of new larger buttons that help patients easily access new optional […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-09-12 09:00:222018-01-05 13:13:53Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler
A patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines CATEGORY: Featured Monday, September 11, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We continue implementation of our strategy to work with leading infectious disease physicians in the United States and Australia and […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-09-11 09:52:482018-01-05 13:14:01AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus
Wednesday, September 6, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “The R&D tax rebate is an important source of non-dilutive capital and we appreciate the Australian government’s support as we develop our novel bacteriophage therapies aimed at combatting the growing global threat of antibiotic resistance” SAN DIEGO–(BUSINESS […]
04 Sep 2017 – link here We’re thrilled to announce that Adherium has received U.S. Food and Drug Administration (FDA) 510(K) clearance for its new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler. The SmartTouch for Symbicort® is a device installed onto a patient’s inhaler to monitor and encourage medication adherence as part of a self-management […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-09-04 12:18:092018-01-05 13:14:14Adherium Receives FDA Clearance for Smartinhaler sensor for AstraZeneca’s Symbicort inhaler
BioScience Managers commits AUS$10M to new joint venture with Canary Medical to serve as a platform to collect and monetize data from implantable and wearable medical devices. Vancouver, British Columbia, Aug 1, 2017 – Canary Medical (Canary) is pleased to announce the formation of CHARM Informatics Pty Ltd (CHARM), in collaboration with BioScience Managers Pty Ltd […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2017-09-02 00:21:032018-06-13 00:22:57Canary Medical and BioScience Managers form CHARM Informatics
BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support Bioscience Managers’ and Downing’s Life Sciences Investments London, UK and Melbourne, Australia, 31 July 2017 – Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers) announces today that it has appointed Elizabeth Klein as an Investment Consultant, to facilitate BioScience Managers’ UK […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-07-31 12:24:532018-01-03 12:51:19BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support Bioscience Managers’ and Downing’s Life Sciences Investments
9 June 2017:link here Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of Arik Anderson as Group Chief Executive Officer (CEO). Founder and past Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-06-09 12:28:172018-01-05 13:14:20Adherium Appoints New CEO to Drive Global Growth
US-based CEO aligns with Avita’s increasing US orientation with BARDA contract, completed Phase 3 trial, imminent PMA submission, and pending US approval & commercialization • Mike Perry former Novartis Executive – Prior SVP & Chief Scientific Officer of Business Development and previous Chief Scientific Officer of Novartis’ Cell & Gene Therapy Unit • Adam Kelliher […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-06-02 12:30:212018-01-05 13:14:26Dr Michael S. Perry appointed Avita Medical CEO
CATEGORY: Featured Wednesday, May 31, 2017 4:05 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D. as Chief Executive Officer, […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-31 12:35:262018-01-05 19:41:37AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer
Directors take up to 100 per cent of fees in shares • Follows shareholder approval of employee share plan in November last year Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom, 23 May 2017 —link here The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH; OTCQX: AVMXY), have shown a strong […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-23 13:14:532018-01-05 13:14:32Avita Medical’s Board show confidence in company by taking payment in shares
Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler
/in Adherium, Portfolio CompaniesAdherium today announced it has released SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology, for AstraZeneca’s Turbuhaler medication. SmartTurbo Model 4 includes usability improvements to make the installation and removal of the Turbuhaler easier for older patients with COPD. The device also features a series of new larger buttons that help patients easily access new optional […]
AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus
/in Armata Pharmaceuticals, Portfolio CompaniesA patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines CATEGORY: Featured Monday, September 11, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We continue implementation of our strategy to work with leading infectious disease physicians in the United States and Australia and […]
AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive
/in Armata Pharmaceuticals, Portfolio CompaniesWednesday, September 6, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “The R&D tax rebate is an important source of non-dilutive capital and we appreciate the Australian government’s support as we develop our novel bacteriophage therapies aimed at combatting the growing global threat of antibiotic resistance” SAN DIEGO–(BUSINESS […]
Adherium Receives FDA Clearance for Smartinhaler sensor for AstraZeneca’s Symbicort inhaler
/in Adherium, Portfolio Companies04 Sep 2017 – link here We’re thrilled to announce that Adherium has received U.S. Food and Drug Administration (FDA) 510(K) clearance for its new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler. The SmartTouch for Symbicort® is a device installed onto a patient’s inhaler to monitor and encourage medication adherence as part of a self-management […]
Canary Medical and BioScience Managers form CHARM Informatics
/in BioSciences Managers, Canary MedicalBioScience Managers commits AUS$10M to new joint venture with Canary Medical to serve as a platform to collect and monetize data from implantable and wearable medical devices. Vancouver, British Columbia, Aug 1, 2017 – Canary Medical (Canary) is pleased to announce the formation of CHARM Informatics Pty Ltd (CHARM), in collaboration with BioScience Managers Pty Ltd […]
BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support Bioscience Managers’ and Downing’s Life Sciences Investments
/in BioSciences ManagersBioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support Bioscience Managers’ and Downing’s Life Sciences Investments London, UK and Melbourne, Australia, 31 July 2017 – Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers) announces today that it has appointed Elizabeth Klein as an Investment Consultant, to facilitate BioScience Managers’ UK […]
Adherium Appoints New CEO to Drive Global Growth
/in Adherium, Portfolio Companies9 June 2017:link here Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of Arik Anderson as Group Chief Executive Officer (CEO). Founder and past Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the […]
Dr Michael S. Perry appointed Avita Medical CEO
/in Avita Medical, Portfolio CompaniesUS-based CEO aligns with Avita’s increasing US orientation with BARDA contract, completed Phase 3 trial, imminent PMA submission, and pending US approval & commercialization • Mike Perry former Novartis Executive – Prior SVP & Chief Scientific Officer of Business Development and previous Chief Scientific Officer of Novartis’ Cell & Gene Therapy Unit • Adam Kelliher […]
AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer
/in Armata Pharmaceuticals, Portfolio CompaniesCATEGORY: Featured Wednesday, May 31, 2017 4:05 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D. as Chief Executive Officer, […]
Avita Medical’s Board show confidence in company by taking payment in shares
/in Avita Medical, Portfolio CompaniesDirectors take up to 100 per cent of fees in shares • Follows shareholder approval of employee share plan in November last year Northridge, CA, USA, Perth, Australia and Cambridge, United Kingdom, 23 May 2017 —link here The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH; OTCQX: AVMXY), have shown a strong […]